Skip to main content


Excited to announce our new analysis from the Phase 3 PRECISION study is now published in Hypertension, a journal of the American Heart Association.

As an author and a PRECISION investigator, I’m proud to share this comprehensive analysis evaluating the efficacy and safety of a novel treatment in patients with chronic kidney disease and confirmed resistant hypertension.

Key highlights:
1.       Robust evidence supporting blood pressure management in a population with high cardiovascular risk.
2.       Safety profile consistent with the Phase 3 PRECISION study.
3.       Potential implications for clinical practice in managing resistant hypertension among CKD patients.